Dr. Galsky discusses key findings from phase 2 trial of MIBC regimen

“The complete clinical response rate of 48% was somewhat surprising, although consistent with our assumptions in terms of the statistical design of the study,” says Matthew Galsky, MD.

In a video filmed during the 2021 ASCO Annual Meeting, Matthew Galsky, MD, shares notable findings from the abstract, “Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in patients with muscle-invasive bladder cancer (MIBC): HCRN GU 16-257,” for which he served as a study author. Galsky is Professor of Medicine (Hematology and Medical Oncology) and Acting Chief of the Division of Hematology and Medical Oncology for the Mount Sinai Health System, New York City, New York.